KDR and neoplasm: In conclusion, our data and the many reports on VEGFR-2 will facilitate the evaluation of our xenogeneic VEGFR-2 DNA vaccine in tumor bearing animals, ranging from preliminary rodent models to highly translational models of spontaneous tumors in pet dogs.